Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code AGR

16. Specific lobbying issues

Climate Change
---H.R.7393/S.3894: The Growing Climate Solutions Act of 2020
---Climate Leadership and Environmental Action for our Nations (CLEAN) Future Act (Discussion Draft House)
---RFI from House Select Committee on the Climate Crisis

Foreign Agricultural Biotechnology Laws and Regulations
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
---Japan Biotechnology Regulations
---Korea Biotechnology Regulations

Funding for Biomass Crop Assistance Program
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021

Funding for the USDA
---H.R.7610:Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---Biotechnology and Agriculture Trade Program
---Farm Bill Programs Energy Title IX

Genetically Engineered (GE) Animals
---H.R.3771/S.1903: Advancing Emergency Preparedness Through One Health Act of 2019
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
------Amendment on GE Salmon Labeling
---FDA Regulatory Approach to Animal Biotechnology
---FDA Proposed Guidance on Gene Editing

Genetically Engineered (GE) Plants
---EPA Regulation of Plant Incorporated Protectants (PIPs)
---EPA Regulatory Approach to Gene Editing
---FDA Proposed Guidance on Gene Editing

The United States-Mexico-Canada Agreement (USMCA)
---Ag-Biotech Provisions

US-China Trade Agreement
---Ag-Biotech Provisions

US-EU Trade Agreement
---Ag-Biotech Provisions

US-Japan Trade Agreement
---Ag-Biotech Provisions

US-UK Trade Agreement
---Ag-Biotech Provisions

USDA/APHIS Agricultural Biotechnology Regulations
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---Regulatory Treatment of Gene Edited Products
---The Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient (SECURE) Rule under the Plant Protection Act
---USDA Part 340 Draft Rule

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR), Natl Economic Council (NEC), Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ANI

16. Specific lobbying issues

Genetically Engineered (GE) Animals
---H.R.3771/S.1903: Advancing Emergency Preparedness Through One Health Act of 2019
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---H.R.7610:Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
------Amendment on GE Salmon Labeling
---FDA Regulatory Approach to Animal Biotechnology
---FDA Proposed Guidance on Gene Editing
---USDA Agriculture Innovation Agenda

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Agriculture - Dept of (USDA), Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

Coronavirus (COVID-19) Pandemic
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---S. 1624: Health, Economic Assistance, Liability Protection, and Schools (HEALS) Act
---H.R.8337:Continuing Appropriations Act, 2021 and Other Extensions Act

Funding for Antimicrobial Resistance Programs
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---H.R.7614: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021
---S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---Health Defense Operations Funding Designation
---H.R.7614:Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Funding for Biofuels
---H.R.2: The Moving Forward Act of 2020
---H.R.6379: Take Responsibility for Workers and Families Act of 2020
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---H.R.7612: Department of the Interior, Environment, and Related Agencies Appropriations Act for FY 2021
---H.R.7613: Energy and Water Development and Related Agencies Appropriations Act for FY 2021
---Incentives for Sustainable Aviation Fuels
---H.R.7616: Transportation, and Housing and Urban Development, and Related Agencies Act for FY 2021

Funding for Biomass Crop Assistance Program
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021

Funding for Biorefineries
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---H.R.7613:Energy and Water Development and Related Agencies Appropriations Act for FY 2021

Funding for Coronavirus (COVID-19) Small Business Loans
--- H.R.266: Paycheck Protection Program and Health Care Enhancement Act

Funding for FDA
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021

Funding for Health Resources and Services Administration (HRSA) - Vaccine Injury Compensation Program (VICP)
---H.R.7614: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Funding for National Institutes of Health
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---H.R.7614: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Funding for Renewable Chemicals/Bio-based Products
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---H.R.7613: Energy and Water Development and Related Agencies Appropriations Act for FY 2021

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---H.R.7614: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021
---Funding for 2020-21 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic

Funding for the HHS Office of Infectious Disease and HIV/AIDS Policy
---H.R.7614: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Funding for the USDA
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---Biotechnology and Agriculture Trade Program
---Farm Bill Programs Energy Title IX

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CHM

16. Specific lobbying issues

Funding for Renewable Chemicals/Bio-based Products
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---H.R.7613: Energy and Water Development and Related Agencies Appropriations Act for FY 2021

Renewable Chemicals/Bio-based Products (Non-Funding)
---H.R.2051/S.999: Sustainable Chemistry Research and Development Act of 2019
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---H.R.6395: William M. (Mac) Thornberry National Defense Authorization Act for FY 2021
---S.4049: National Defense Authorization Act for FY 2021
---Climate Leadership and Environmental Action for our Nations (CLEAN) Future Act (Discussion Draft House)
---Implementation of the Agriculture Improvement Act of 2018
---Investment Tax Credit
---Production Tax Credit
---Sustainable Chemistry Research and Development

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Asia Pacific Economic Cooperation Forum
- - - Biologics Regulations
- - - Intellectual Property Issues

Bayh-Dole Act/Tech Transfer
---Bayh-Dole 40th Anniversary
---Domestic Manufacturing Requirement
---March-In Rights

Compulsory licensing
---S.2387: We Protect American Investment in Drugs Act of 2019

Coronavirus (COVID-19) Pandemic
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---Restrictions on Intellectual Property Rights

Drug Patenting
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---S.1416/H.R.4398/H.R.3991/H.R.5133: Affordable Prescriptions for Patients Act of 2019

Intellectual Property International Enforcement
---China
---S.3952: A bill to require the imposition of sanctions with respect to foreign persons that have engaged in significant theft of trade secrets of United States persons, and for other purposes.

Patent Reform
---H.R.7259/S.2814: Patents for Humanity Program Improvement Act of 2020

Patenting of Biological Inventions
---Section 101 Modernization

The United States-Mexico-Canada Agreement (USMCA)
---Implementation of United States-Mexico-Canada Agreement (USMCA)
---IP Provisions

US-China Trade Agreement
---IP Provisions

US-EU Trade Agreement
---IP Provisions

US-Japan Trade Agreement
---IP Provisions

US-Kenya Trade Agreement
---IP Provisions

US-UK Trade Agreement
---IP Provisions

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO), Office of the Vice President of the United States, Commerce - Dept of (DOC), Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CSP

16. Specific lobbying issues

Genetically Engineered (GE) Animals
---H.R.3771/S.1903: Advancing Emergency Preparedness Through One Health Act of 2019
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
------Amendment on GE Salmon Labeling
---FDA Regulatory Approach to Animal Biotechnology

Drug Importation
---Executive Order on Increasing Drug Importation to Lower Prices for American Patients

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Natl Economic Council (NEC), Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ENG

16. Specific lobbying issues

Biofuels (Non-Funding)
---H.R.2: The Moving Forward Act of 2020
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---H.R.7330: Growing Renewable Energy and Efficiency Now (GREEN) Act
---S.1288: Clean Energy for America Act of 2019
---S.3938: A bill to extend Federal guidance concerning the use of certain alcohol-based hand sanitizer during the coronavirus public health emergency, and for other purposes.
---RFI from House Select Committee on the Climate Crisis
---Sustainable Aviation Fuels Tax Credit

Climate Change
---H.R.7393/S.3894: The Growing Climate Solutions Act of 2020
---Climate Leadership and Environmental Action for our Nations (CLEAN) Future Act (Discussion Draft House)
---RFI from House Select Committee on the Climate Crisis

Funding for Biofuels
---H.R.2: The Moving Forward Act of 2020
---H.R.6379: Take Responsibility for Workers and Families Act of 2020
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---H.R.7612: Department of the Interior, Environment, and Related Agencies Appropriations Act for FY 2021
---H.R.7613: Energy and Water Development and Related Agencies Appropriations Act for FY 2021
---Incentives for Sustainable Aviation Fuels
---H.R.7616: Transportation, and Housing and Urban Development, and Related Agencies Act for FY 2021

Funding for Biomass Crop Assistance Program
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021

Funding for Biorefineries
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---H.R.7613: Energy and Water Development and Related Agencies Appropriations Act for FY 2021

RFS (Renewable Fuel Standard)
---H.R.3006: Support RFS Integrity Act of 2019
---H.R.4385: Small Refinery Exemption Fairness Act of 2019
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
---S.3986: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes
---Cellulosic Registration Applications for Corn Kernel Fiber
---Climate Leadership and Environmental Action for our Nations (CLEAN) Future Act (Discussion Draft House)
---Economic Hardship Waiver of the Renewable Volume Obligations (RVO) for 2020
---Implementation of the Agriculture Improvement Act of 2018
---Proposed Rule to set 2021 Renewable Volume Obligations (RVOs) under the Renewable Fuel Standard and the 2022 RVO for Biomass-based Diesel
---RFI from House Select Committee on the Climate Crisis
---RFS Reform
---Small Refinery Waivers

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Environmental Protection Agency (EPA), Natl Economic Council (NEC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FOO

16. Specific lobbying issues

Genetically Engineered (GE) Animals
---H.R.3771/S.1903: Advancing Emergency Preparedness Through One Health Act of 2019
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
------Amendment on GE Salmon Labeling
---FDA Regulatory Approach to Animal Biotechnology
---USDA Agriculture Innovation Agenda
---FDA Proposed Guidance on Gene Editing

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Natl Economic Council (NEC), Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FUE

16. Specific lobbying issues

Biofuels (Non-Funding)
---H.R.2: The Moving Forward Act of 2020
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---H.R.7330: Growing Renewable Energy and Efficiency Now (GREEN) Act
---S.1288: Clean Energy for America Act of 2019
---S.3938: A bill to extend Federal guidance concerning the use of certain alcohol-based hand sanitizer during the coronavirus public health emergency, and for other purposes.
---RFI from House Select Committee on the Climate Crisis
---Sustainable Aviation Fuels Tax Credit

Climate Change
---H.R.7393/S.3894: The Growing Climate Solutions Act of 2020
---Climate Leadership and Environmental Action for our Nations (CLEAN) Future Act (Discussion Draft House)
---RFI from House Select Committee on the Climate Crisis

Funding for Biofuels
---H.R.2: The Moving Forward Act of 2020
---H.R.6379: Take Responsibility for Workers and Families Act of 2020
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---H.R.7612: Department of the Interior, Environment, and Related Agencies Appropriations Act for FY 2021
---H.R.7613: Energy and Water Development and Related Agencies Appropriations Act for FY 2021
---Incentives for Sustainable Aviation Fuels
---H.R.7616: Transportation, and Housing and Urban Development, and Related Agencies Act for FY 2021

Funding for Biomass Crop Assistance Program
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021

Funding for Biorefineries
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---H.R.7613: Energy and Water Development and Related Agencies Appropriations Act for FY 2021

RFS (Renewable Fuel Standard)
---H.R.3006: Support RFS Integrity Act of 2019
---H.R.4385: Small Refinery Exemption Fairness Act of 2019
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
---S.3986: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes
---Cellulosic Registration Applications for Corn Kernel Fiber
---Climate Leadership and Environmental Action for our Nations (CLEAN) Future Act (Discussion Draft House)
---Economic Hardship Waiver of the Renewable Volume Obligations (RVO) for 2020
---Implementation of the Agriculture Improvement Act of 2018
---Proposed Rule to set 2021 Renewable Volume Obligations (RVOs) under the Renewable Fuel Standard and the 2022 RVO for Biomass-based Diesel
---RFI from House Select Committee on the Climate Crisis
---RFS Reform
---Small Refinery Waivers

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Environmental Protection Agency (EPA), Natl Economic Council (NEC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

H.R.34: 21st Century Cures Act 2.0
---RFI from House Energy and Commerce Committee

340B Drug Discount Program
---Executive Order on Affordable Life-saving Medications
---H.R. 7614: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021
---Program Implementation & Oversight

Reimbursement and Coverage of Innovative Products
---Executive order on Lowering Drug Prices by Putting America First

Drug Importation
---Executive Order on Increasing Drug Importation to Lower Prices for American Patients

Antibiotic & Diagnostic Tax Credit

Asia Pacific Economic Cooperation Forum
---Biologics Regulations
---Intellectual Property Issues

Biodefense Research, Development and Procurement Issues (Nonfunding)
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Families First Coronavirus Response Act of 2020
---H.R. 748: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.4100/S.1712: DISARM Act of 2019
---S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020
---S.4231: Preparing for the Next Pandemic Act of 2020
---Strategic National Stockpile
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---H.R.7537: Infectious Disease Therapies Research and Innovation Act
---H.R.7556: To amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research.
---H.R.7555: To amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities.
---H.R.7537: Infectious Disease Therapies Research and Innovation Act
---Implementation of the Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019
---Executive Order on Buy American
---Executive Order on Modernizing Influenza Vaccines
---Gene editing
---Implementation of 21st Century Cures Act of 2016
---Implementation of Medical Countermeasure Innovation Act of 2016
---MCM Manufacturing & Capacity
---MCM R&D Incentives
---National Biodefense Strategy
---Senate HELP Pandemic Preparedness White Paper
---Tropical Disease Priority Review Voucher (PRV) Program

Biosimilars
---Biosimilar Copay
---BSUFA
---Implementation and Reauthorization of the Biosimilar User Fee Act of 2017
---Reimbursement

Climate Change
---RFI from House Select Committee on the Climate Crisis

Coronavirus (COVID-19) Pandemic
---H.R.4100/S.1712: DISARM Act of 2019
---H.R.5076/S.1872: Protecting Seniors through Immunizations Act of 2019
---H.R.7917: IGNITE American Innovation Act
---H.R.6260/S.3545: Reciprocity Ensures Streamlined Use of Lifesaving Treatments for Coronavirus Patients Act of 2020
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---S.4775: The Delivering Immediate Relief to America's Families, Schools and Small Business Act
---H.R.7288: The Taxpayer Research and Coronavirus Knowledge (TRACK) Act
---COVID-19 Vaccine and Therapeutic Development
---Coverage for Covid Tx
---Drug Supply Chain Management
---Funding for Countermeasure Injury Compensation Program
---Healthcare Disparities
---Home Administration of Part B Drugs
---Liability
---Medicare reimbursement policies
---Patient Cost-Sharing and Smoothing
---Pricing-related Provisions
---R&D Funding for Medical Countermeasures
---Restrictions on Intellectual Property Rights
---Senate HELP Pandemic Preparedness White Paper

Drug Evaluation and Review
---S.1617: Second Look at Drug Patents Act of 2019
---H.R.7269/S.3872: Promising Pathway Act
---Compassionate Use/Expanded Access
---Expedited Pathways
---Priority Review Voucher Programs

Drug Manufacturing, Quality & Distribution
---Drug Shortages
---Drug Supply Chain Management
---Executive Order on Buy American

Drug Patenting
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---S.1416/H.R.4398/H.R.3991/H.R.5133: Affordable Prescriptions for Patients Act of 2019

Drug Pricing
---H.R.3: Lower Drug Costs Now Act of 2019
---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.1093/S.378: Stop Price Gouging Act of 2019
---H.R.1425: The Patient Protection and Affordable Care Enhancement Act of 2020
---S.1895: Lower Health Care Costs for Patients Act of 2019
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---S.1617: Second Look at Drug Patents Act of 2019
---H.R.19/S.3129: Lower Costs, More Cures Act of 2019
---H.R.2069/S.474: Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019
---H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019
---H.R.1188/S.366: Forcing Limits on Abusive and Tumultuous prices (FLAT) prices Act of 2019
---H.R.2113: Prescription Drug STAR Act of 2019
---H.R.2376/S.1227: Prescription Pricing for the People Act of 2019
---H.R.2387: Stop The Overuse of Petitions and Get Affordable Medicines to Enter Soon (STOP GAMES) Act of 2019
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---H.R.3199: Terminating the Extension of Rights Misappropriated (TERM) Act of 2019
---H.R.3991: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---H.R.7288: The Taxpayer Research and Coronavirus Knowledge (TRACK) Act
---S.1416/H.R.4398/H.R.3991/H.R.5133: Affordable Prescriptions for Patients Act of 2019
---H.R.7614: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---CMMI Authority
---Executive Order on Buy American
---Executive Order on Access to Affordable Life-saving Medications
---Executive Order on Increasing Drug Importation to Lower Prices for American Patients
---Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen
---General
---International Pricing Index Proposal
---Most Favored Nation Executive Order
---Proposed Federal Price Caps on COVID-19 Therapeutics and Vaccines

Foreign Drug Data Protection Laws
---Regulatory Harmonization

Funding for Antimicrobial Resistance Programs
---S. 1624: Health, Economic Assistance, Liability Protection, and Schools (HEALS) Act
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---H.R.7614: Labor, Health and Human services, Education, and Related Agencies Appropriations Act for FY 2021
---H.R.748: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---S.4760:Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R. 8337: Continuing Appropriations Act, 2021 and other Extensions Act of 2020
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act of 2020
---H.R.748: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---H.R.7614: Labor, Health and Human services, Education, and Related Agencies Appropriations Act for FY 2021
---S. 1624: Health, Economic Assistance, Liability Protection, and Schools (HEALS) Act
---Health Defense Operations Funding Designation
---H.R.7537: Infectious Disease Therapies Research and Innovation Act
---H.R.7556: To amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research.
---H.R.7555: To amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities.
---H.R.7537: Infectious Disease Therapies Research and Innovation Act

Funding for FDA
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021

Funding for Health Resources and Services Administration (HRSA) - Vaccine Injury Compensation Program (VICP)
---H.R.7614: Labor, Health and Human services, Education, and Related Agencies Appropriations Act for FY 2021

Funding for National Institutes of Health
---H.R. 8337: Continuing Appropriations Act, 2021 and other Extensions Act of 2020
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act of 2020
---H.R.748: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R. 8337: Continuing Appropriations Act, 2021 and other Extensions Act of 2020
---H.R.748: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---H.R.7614: Labor, Health and Human services, Education, and Related Agencies Appropriations Act for FY 2021
---Funding for 2020-21 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic

Funding for the HHS Office of Infectious Disease and HIV/AIDS Policy
---H.R.7614: Labor, Health and Human services, Education, and Related Agencies Appropriations Act for FY 2021

Medicaid
---H.R.5741: Strengthening Innovation in Medicare and Medicaid Act of 2020
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---S.3013: Encouraging Innovation Benefit Design to Lower Costs for Seniors Act of 2019
---Alternative payment arrangements for gene therapies
---Average Manufacturer Price Calculations
---Drug Benefit Design
---Pricing and Rebates
---Value-Based Purchasing (VBP) Rule

Medicare Expansion
---H.R.5741: Strengthening Innovation in Medicare and Medicaid Act of 2020

Orphan Drug Issues
---H.R.4439/S.4010: Creating Hope Reauthorization Act of 2019
---H.R.4712: Fairness in Orphan Drug Exclusivity Act of 2019
---Tax Credit

Rare Pediatric Disease Priority Review
---H.R. 8337: Continuing Appropriations Act, 2021 and other Extensions Act of 2020
---H.R.4439/S.4010: Creating Hope Reauthorization Act of 2019

Reimbursement and Coverage of Innovative Products
---H.R.19/S.3129: Lower Costs, More Cures Act of 2019
---H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019
---H.R.3: Lower Drug Costs Now Act of 2019
---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019
---H.R.5741: Strengthening Innovation in Medicare and Medicaid Act of 2020
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act of 2020
---S.2326: New Opportunities for Value that Extend Lives (NOVEL) Act of 2019
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---Administration Rebate Rule
---CMMI Authority
---Executive Order on Lowering Drug Prices by Putting America First
---Executive Order on Access to Affordable Life-Saving Medications
---Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen
---In-Home Administration of Part B Drugs
---International Pricing Index Proposal
---Medicare Part B Physician-Administered Products
---Patient Cost-Sharing and Smoothing
---Protected Classes
---Step Therapy
---Support of Patient Premiums and Cost-Sharing Obligations
---Value-Based Purchasing (VBP) Rule
---Value-based Contracting and Communications

The United States-Mexico-Canada Agreement (USMCA)
---Implementation of United States-Mexico-Canada Agreement (USMCA)
---IP Provisions

Trade and Foreign Drug Price Controls

US-China Trade Agreement
---IP Provisions

US-UK Trade Agreement
---Digital Trade
---IP Provisions
---Market Access
---Regulatory Harmonization

Vaccines and Infectious Diseases
---H.R.2862/S.1619: Vaccine Awareness Campaign to Champion Immunization Nationally and Enhance Safety (VACCINES) Act of 2019
---H.R.4100/S.1712: DISARM Act of 2019
---H.R.5076/S.1872: Protecting Seniors through Immunizations Act of 2019
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act of 2020
---H.R.748: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---H.R.7614: Labor, Health and Human services, Education, and Related Agencies Appropriations Act for FY 2021
---S.4509: Vaccine And Coverage Certainty (VACC) Act
---Adult Immunization Education
---Countermeasure Injury Compensation Program
---Implementation of the Families First Coronavirus Response Act of 2020
---MCM Manufacturing & Capacity
---MCM R&D Incentives
---Maternal Immunization
---Operation Warp Speed/ACTIV
---S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020
---Vaccine Injury Compensation Program
---Vaccine Quality Measure
---Vaccine Safety
---Vaccine and Anti-Microbial Resistance Product Development and Incentives

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), U.S. Trade Representative (USTR), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Natl Economic Council (NEC), Office of the Vice President of the United States, Natl Security Council (NSC), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HOM

16. Specific lobbying issues

Biodefense Research, Development and Procurement Issues (Nonfunding)
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---H.R.4100/S.1712: DISARM Act of 2019
---H.R.748: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act 2020
---H.R.6201: Families First Coronavirus Response Act 2020
---S.4231: Preparing for the Next Pandemic Act of 2020
---H.R.7537: Infectious Disease Therapies Research and Innovation Act
---H.R.7556: To amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research.
---H.R.7555: To amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities.
---H.R.7537: Infectious Disease Therapies Research and Innovation Act
---Executive Order on Modernizing Influenza Vaccines
---Executive Order on Lowering Drug Prices by Putting America First
---Executive Order on Access to Affordable Life-Saving Medications
---Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen
---Gene editing
---Implementation of 21st Century Cures Act of 2016
---Implementation of Medical Countermeasure Innovation Act of 2016
---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019
---MCM Manufacturing & Capacity
---MCM R&D Incentives
---National Biodefense Strategy
---S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020
---Strategic National Stockpile
---Tropical Disease Priority Review Voucher (PRV) Program

Funding for Antimicrobial Resistance Programs
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---H.R.7614: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021
---S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---Health Defense Operations Funding Designation
---H.R.7614: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

Biodefense Research, Development and Procurement Issues (Nonfunding)
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---Executive Order on Modernizing Influenza Vaccines
---Executive Order on Buy American
---Gene Editing
---Implementation of 21st Century Cures Act of 2016
---Implementation of Medical Countermeasure Innovation Act of 2016
---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019
---National Biodefense Strategy
---Tropical Disease Priority Review Voucher (PRV) Program

Coronavirus (COVID-19) Pandemic
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---H.R.7288: The Taxpayer Research and Coronavirus Knowledge (TRACK) Act
---COVID-19 Vaccine and Therapeutic Development
---Pricing-related Provisions
---R&D Funding for Medical Countermeasures
---Restrictions on Intellectual Property Rights

Funding for Antimicrobial Resistance Programs
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---H.R.7610: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---H.R.7614:Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021
---S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---H.R.7614:Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021
---Health Defense Operations Funding Designation

Funding for National Institutes of Health
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---H.R.7614:Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---H.R.7614:Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021
---Funding for 2020-21 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

21st Century Cures Act 2.0
---RFI from House Energy and Commerce Committee

Coronavirus (COVID-19) Pandemic
---H.R.4100/S.1712: DISARM Act of 2019
---H.R.5076/S.1872: Protecting Seniors through Immunizations Act of 2019
---H.R.7288: The Taxpayer Research and Coronavirus Knowledge (TRACK) Act
---COVID-19 Vaccine and Therapeutic Development
---Home Administration of Part B Drugs
---Patient Cost-Sharing and Smoothing
---Pricing-related Provisions

Drug Pricing
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.1093/S.378: Stop Price Gouging Act of 2019
---H.R.2376/S.1227: Prescription Pricing for the People Act of 2019
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---H.R.7288: The Taxpayer Research and Coronavirus Knowledge (TRACK) Act
---S.1416/H.R.4398/H.R.3991/H.R.5133: Affordable Prescriptions for Patients Act of 2019
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---CMMI Authority
---General
---International Pricing Index Proposal
---H.R.7614: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021
---Potential Administration Executive Orders
---Pricing-related Provisions

Medicaid
---H.R.5741: Strengthening Innovation in Medicare and Medicaid Act of 2020
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---Alternative payment arrangements for gene therapies
---Average Manufacturer Price Calculations
---Pricing and Rebates
---Value-Based Purchasing (VBP) Rule

Medicare Expansion
---H.R.5741: Strengthening Innovation in Medicare and Medicaid Act of 2020

Reimbursement and Coverage of Innovative Products
---H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare Part B Prescription Drug Models
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---S.2326: New Opportunities for Value that Extend Lives (NOVEL) Act of 2019
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---Administration Rebate Rule
---CMMI Authority
---Home Administration of Part B Drugs
---International Pricing Index Proposal
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---Patient Cost-Sharing and Smoothing
---Protected Classes
---Step Therapy
---Support of Patient Premiums and Cost-Sharing Obligations
---Value-based Contracting and Communications

Vaccines and Infectious Diseases
---H.R.4100/S.1712: DISARM Act of 2019
---H.R.5076/S.1872: Protecting Seniors through Immunizations Act of 2019
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), White House Office, Natl Economic Council (NEC), Office of the Vice President of the United States

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code SMB

16. Specific lobbying issues

Capital Formation Incentives
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---Incentives for Sustainable Aviation Fuels
---H.R.7537: Infectious Disease Therapies Research and Innovation Act
---H.R.7556: To amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research.
---H.R.7555: To amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities.
H.R.7537: Infectious Disease Therapies Research and Innovation Act
H.R.7505: American Innovation Act

Capital Market Enhancements
---Accredited Investor Definition
---Amended Definition of Smaller Reporting Company
---Encouraging Employee Ownership Act
---SEC Rule 701
---SEC Small Business Forum
---Small Business Capital Formation Enhancement Act

Coronavirus (COVID-19) Pandemic
---H.R.7917 IGNITE American Innovation Act
---H.R.7661: Covid ECG Extension Act
---H.R. 7917 IGNITE American Innovation Act
---Small Business Loans
---R&D Credit Temporary Refundability

Coronavirus (COVID-19) Small Business Loans (Non-Funding)
---H.R.266: Paycheck Protection Program and Health Care Enhancement Act of 2020
---S.4775: The Delivering Immediate Relief to America's Families, Schools and Small Business Act
---Affiliation
---CARES Act Payroll Protection Loan Program Implementation
---Eligibility
---Payroll Tax Deferral

Funding for Coronavirus (COVID-19) Small Business Loans
--- H.R.266: Paycheck Protection Program and Health Care Enhancement Act

Proxy Advisory Services
---Impact of Policies on Small Public Companies

Sarbanes Oxley Section 404 (b)
---H.R.3886/S.452: Fostering Innovation Act of 2019
---Small Issuer Exemption

Small Business Innovation Research (SBIR) Program

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Securities & Exchange Commission (SEC), Small Business Administration (SBA), Treasury - Dept of

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Biofuels (Non-Funding)
---H.R.2: The Moving Forward Act
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---H.R.6379: Take Responsibility for Workers and Families Act of 2020
---Climate Leadership and Environmental Action for our Nations (CLEAN) Future Act (Discussion Draft House)
---Incentives for Sustainable Aviation Fuels

Capital Formation Incentives
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---Incentives for Sustainable Aviation Fuels
---H.R.7537: Infectious Disease Therapies Research and Innovation Act
---H.R.7556: To amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research.
---H.R.7555: To amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities.
---H.R.7537: Infectious Disease Therapies Research and Innovation Act
---H.R.7505: American Innovation Act
---Reform of Net Operating Loss Rules

Coronavirus (COVID-19) Pandemic
---H.R.7917: IGNITE American Innovation Act

Orphan Drug Issues
---Tax Credit

Renewable Chemicals/Bio-based Products (Non-Funding)
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---Climate Leadership and Environmental Action for our Nations (CLEAN) Future Act (Discussion Draft House)
---Investment Tax Credit
---Production Tax Credit

Research & Development Tax Credit Reforms
---H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES) Act of 2020
---Expensing of R&D Expenditures
---Incentives for Sustainable Aviation Fuels
---R&D Credit Temporary Refundability
---R&D Payroll Credit
---H.R.4549: American Innovation and Competitiveness Act (AICA) of 2019

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Treasury - Dept of, Small Business Administration (SBA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

CFIUS and Foreign Investment
---Implementation of Foreign Investment Risk Review Modernization Act (FIRRMA) of 2017

Drug Importation
---Executive Order on Increasing Drug Importation to Lower Prices for American Patients

Drug Pricing
---Executive Order on Buy American
---Executive Order on Access to Affordable Life-saving Medications
---Executive Order on Increasing Drug Importation to Lower Prices for American Patients
---Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen
---International Pricing Index Proposal
---Most Favored Nation Executive Order

Foreign Agricultural Biotechnology Laws and Regulations
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
---Korea Biotechnology Regulations
---Mexico Biologics Regulations

Foreign Drug Data Protection Laws
---Regulatory Harmonization

Intellectual Property International Enforcement
---China
---S.3952: A bill to require the imposition of sanctions with respect to foreign persons that have engaged in significant theft of trade secrets of United States persons, and for other purposes.

The United States-Mexico-Canada Agreement (USMCA)
---Ag-Biotech Provisions
---Implementation of United States-Mexico-Canada Agreement (USMCA)
---IP Provisions

Trade and Foreign Drug Price Controls

US-China Trade Agreement
---Ag-Biotech Provisions
---IP Provisions

US-EU Trade Agreement
---Ag-Biotech Provisions
---IP Provisions

US-Japan Trade Agreement
---Ag-Biotech Provisions
---IP Provisions

US-Kenya Trade Agreement
---Digital Trade
---IP Provisions
---Market Access
---Regulatory Harmonization

US-UK Trade Agreement
---Ag-Biotech Provisions
---Digital Trade
---IP Provisions
---Market Access
---Regulatory Harmonization

World Health Organization (WHO)
---United States Withdrawal from the World Health Organization (WHO)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Treasury - Dept of, Agriculture - Dept of (USDA), Natl Economic Council (NEC), Natl Security Council (NSC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code SCI

16. Specific lobbying issues

Engineering Biology
---H.R.4373 Engineering Biology Research and Development Act
---S.3734: Bioeconomy Research and Development Act of 2020

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes